Linezolid: Safety and efficacy in special populations

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 4, 2011, Pages

  Gould, F Kate ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Adverse events; GRAM positive infection; Oxazolidinone; Toxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CEFTRIAXONE; COCAINE; DALBAVANCIN; GENTAMICIN; LINEZOLID; MONOAMINE OXIDASE INHIBITOR; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; TRICYCLIC ANTIDEPRESSANT AGENT; VANCOMYCIN;

ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; BACTERIAL SKIN DISEASE; BONE INFECTION; BONE MARROW SUPPRESSION; CHOLESTASIS; COMMUNITY ACQUIRED PNEUMONIA; DRUG ANTAGONISM; DRUG COMPETITION; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; HUMAN; INFECTIOUS ARTHRITIS; LACTIC ACIDOSIS; LIVER DYSFUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OPTIC NERVE DISEASE; PANCYTOPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; SEROTONIN SYNDROME; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED KINGDOM; VISUAL IMPAIRMENT;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ENDOCARDITIS, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; GREAT BRITAIN; HUMANS; OSTEOARTHRITIS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

EID: 79955504717     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr071     Document Type: Article

References (41)

1. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009; 59 Suppl 1: S59-74.
2. Lee E, Burger S, Shah J. Linezolid-associated toxic optic neuropathy. Clin Infect Dis 2003; 37: 389-91.
3. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 Suppl 2: ii45-53.
4. Rubinstein E, Isturiz R, Standiford HC et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-31.
5. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials; focus on the oxazolidinone linezolid. Pharmacotherapy 2001; 21: 1010-13.
6. Senneville E, Legout L, Valette M et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004; 54: 798-802.
7. Attassi K, Hershberger E, Alam R et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34: 695-8.
8. Lin YH, Wu VC, Tsai IJ et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28: 345-51.
9. Jaksic B, Martinelli G, Perez-Oteyza J et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42: 597-607.
10. Cohen N, Mihu CN, Seo SK et al. Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15 Suppl 10: 1337-41.
11. Smith PF, Birmingham MC, Meagher AK et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003; 14 Suppl 5: 795-801.
12. Legout L, Senneville E, Gomel JJ et al. Linezolid-induced neuropathy. Clin Infect Dis 2004; 38: 767-8.
13. Rho JP, Sia IG, Crum BA et al. Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004; 79: 927-30.
14. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med 2003; 348: 86-7.
15. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43: 180-7.
16. Meissner HC, Townsend T, Wenman W et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22 Suppl 9: S186-92.
17. Garazzino S, Tovo P-A. Clinical experience with linezolid in infants and children. J Antimicrob Chemother 2011; 66 Suppl 4: iv23-41.
18. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin 2010; 26 Suppl 2: 407-21.
19. Beibei L, Yun C, Mengli C et al. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trails. Int J Antimicrob Agents 2010; 35 Suppl 1: 3-12.
20. Logman JFS, Stephens J, Heeg B et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin 2010; 26 Suppl 7: 1565-78.
21. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53 Suppl 2: 335-44.
22. Cammarata SK, San Pedro GS et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia. Abstract WeP237. Clin Microbiol Infect 2000; 6 Suppl 1: 136.
23. Falagas ME, Vardakas KZ. Benefit-risk assessment of linezolid for serious Gram-positive bacterial infections. Drug Saf 2008; 31 Suppl 9: 753-68.
24. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2010; doi:10.1378/chest.10-1556.
25. Kalil AC, Murthy MH, Hermsen ED et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010; 38: 1910-2.
26. Masterton RG, Galloway A, French G et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008; 62: 5-34.
27. Gould FK, Brindle R, Chadwick PR et al. MRSA Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009; 63: 849-61.
28. Samuel JR, Gould FK. Prosthetic joint infections: single versus combination therapy. J Antimicrob Chemother 2010; 65: 18-23.
29. Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005; 55: 387-90.
30. Razonable RR, Osman DR, Steckelberg JM. Linezolid therapy for orthopaedic infections. Mayo Clin Proc 2004; 9: 1137-44.
31. Jacqueline C, Caillon J, Mabecque VL et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51: 857-64.
32. Murillo O, Domenech A, Euba G et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infect 2008; 57: 229-35.
33. Tsaganos T, Skiadas I, Koutoukas P et al. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in a experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 2008; 62: 381-3.
34. Falagas ME, Manta KG, Ntziora F et al. Linezolid for the treatment of patients with endocarditis: a systemic review of the published evidence. J Antimicrob Chemother 2006; 58: 273-80.
35. Tsona A, Metallidis S, Foroglou N et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother 2010; 22 Suppl 1: 17-9.
36. Viale P, Pagani L, Cristini F et al. Linezolid treatment of central nervous system infections in neuro-surgical patients. Scand J Infect Dis 2002; 34: 456-9.
37. Krueger WA, Kottler B, Will BE et al. Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid. J Clin Microbiol 2004; 42: 929-32.
38. López-Cabezas C, Muner DS, Massa MR et al. Antibiotics in endophthalmitis: microbiological and pharmacokinetic considerations. Curr Clin Pharmacol 2010; 5: 47-54.
39. Horcajada JP, Atienza R, Sarasa M et al. Pharmacokinetics of linezolid in human non-inflamed vitreous after systemic administration. J Antimicrob Chemother 2009; 63 Suppl 3: 550-2.
40. Wilcox MH. Efficacy of linezolid versus comparator therapies in Grampositive infections. J Antimicrob Chemother 2003; 51 Suppl 2: ii27-35.
41. Rafailidis PI, Kouranos VD, Christodoulou C et al. Linezolid for patients with neutropenia: are bacteriostatic agents appropriate? Expert Rev Anti Infect Ther 2009; 7 Suppl 4: 415-22.